Tissue-Repair Peptides

In-vitro and preclinical literature on BPC-157, TB-500, GHK-Cu and KPV: mechanisms, model systems and 20 PubMed-linked references.

✔ PubMed-linked citations   ✔ In-vitro and preclinical only   ✔ Research Use Only

Tissue-repair peptides are short synthetic peptides whose sequences are derived from, or identical to, endogenous fragments studied in models of wound closure, angiogenesis, extracellular-matrix remodeling and inflammation resolution. The compounds in this class (BPC-157, thymosin beta-4/TB-500, GHK-Cu and KPV) act through distinct mechanisms: nitric oxide and growth-factor-receptor signalling, G-actin sequestration and cell migration, copper-dependent modulation of gene expression, and melanocortin-related anti-inflammatory signalling, respectively. The literature is dominated by rodent injury models (tendon, skin, muscle, gastrointestinal, myocardial), ex vivo explants and cultured fibroblast, keratinocyte, endothelial and epithelial cell lines, together with mechanistic reviews. Human clinical data are sparse or absent for most of these peptides, and the references collected here are restricted to in-vitro, preclinical and review literature.

This page collects 30 peer-reviewed references across 6 compounds. Every citation links to its PubMed record so the primary source can be read in full. The selection is limited to in-vitro, ex-vivo and preclinical animal studies and mechanistic reviews; human clinical literature is deliberately excluded because Liv Pure products are supplied for laboratory research only.

BPC-157

Also known as: Body Protection Compound-157; stable gastric pentadecapeptide; PL 14736; sequence GEPPPGKPADDAGLV (15 amino acids, MW ~1419)

Molecular target or pathway: Nitric oxide (NO) system interaction (eNOS, L-NAME/L-arginine responsive); VEGFR2 and FAK-paxillin signalling; modulation of eNOS and COX2 gene expression reported in rat models; no single high-affinity receptor established

Origin: Synthetic pentadecapeptide corresponding to a partial sequence of a protein originally isolated from human gastric juice

BPC-157 has been studied extensively in rat models of gastrointestinal, tendon, ligament, muscle, vascular and nervous-system injury, largely by a single research group at the University of Zagreb. In vitro work includes rat tendon explant outgrowth, tendon fibroblast migration and survival assays, and membrane-potential measurements in HEK293 cells. Reviews summarize proposed interactions with the nitric oxide system, angiogenic growth-factor pathways and endothelial protection; the literature is predominantly preclinical, and the references below are restricted to that subset.

Liv Pure supplies BPC-157 as a lyophilized research reagent with a lot-specific certificate of analysis.

Selected references

  1. Chang CH et al. (2010). Journal of applied physiology. Rat Achilles tendon explants and cultured rat tendon fibroblasts. BPC 157 increased outgrowth of tendon fibroblasts from explants and increased fibroblast migration and survival under oxidative stress, without altering proliferation, with FAK-paxillin pathway activation observed. PMID 21030672 · DOI
  2. Seiwerth S et al. (2021). Frontiers in pharmacology. Review of rat wound models. Reviewed rat incisional, excisional, burn and fistula wound studies and reported that BPC 157 was associated with altered expression of multiple genes in rat excisional skin wounds. PMID 34267654 · DOI
  3. Seiwerth S et al. (2014). Current pharmaceutical design. Review of rat vascular injury models. Reviewed effects of BPC 157 on endothelium, clotting, thrombosis and vessel formation in rats and summarized proposed involvement of NO, VEGF and FAK pathways. PMID 23782145 · DOI
  4. Zivanovic-Posilovic G et al. (2016). European journal of pharmacology. HEK293 cells (membrane voltage) and rat bupivacaine cardiotoxicity model. BPC 157 (1 µM) inhibited bupivacaine-induced membrane depolarization in HEK293 cells and was associated with attenuated ECG disturbances in bupivacaine-treated rats. PMID 27815173 · DOI
  5. Barisic I et al. (2022). Biomedicines. Rat isoprenaline myocardial infarction model. BPC 157 administration was associated with reduced necrosis markers and oxidative stress parameters and with changes in eNOS and COX2 gene expression in isoprenaline-treated rats. PMID 35203478 · DOI

TB-500 (thymosin beta-4)

Also known as: Thymosin beta-4 (Tβ4); TB4; synthetic full-length thymosin beta-4 (43 amino acids, MW ~4963; the actin-binding motif LKKTETQ occupies residues 17-23)

Molecular target or pathway: G-actin sequestration (micromolar-affinity monomeric actin binding); regulation of the SRF-MRTF-G-actin transcriptional pathway; endothelial and keratinocyte chemotaxis; matrix metalloproteinase production

Origin: Endogenous 43-residue peptide present in most vertebrate cells and released by platelets; TB-500 is the synthetic full-length peptide

Thymosin beta-4 is the major intracellular G-actin-sequestering peptide in vertebrate cells, and its extracellular activities have been examined in rat and mouse dermal wound models, HUVEC migration assays, Matrigel implants and models of cardiac and hepatic injury. Research-grade TB-500 is the synthetic full-length peptide, so the mechanistic literature on thymosin beta-4 applies directly. Reviews note that the molecular mechanisms of extracellular beta-thymosins remain incompletely defined.

Liv Pure supplies TB-500 (thymosin beta-4) as a lyophilized research reagent with a lot-specific certificate of analysis.

Selected references

  1. Hannappel E et al. (2007). Annals of the New York Academy of Sciences. Review (biochemistry of beta-thymosins). Reviewed the isolation, sequence and G-actin-sequestering function of thymosin beta-4, including its micromolar dissociation constant with G-actin and conformational folding on actin binding. PMID 17468232 · DOI
  2. Malinda KM et al. (1999). The Journal of investigative dermatology. Rat full-thickness dermal wound model and keratinocyte Boyden chamber assay. Topical or intraperitoneal thymosin beta-4 was associated with increased re-epithelialization, collagen deposition and angiogenesis in rat wounds and stimulated keratinocyte migration 2-3-fold in vitro. PMID 10469335 · DOI
  3. Malinda KM et al. (1997). FASEB journal. Human umbilical vein endothelial cells (HUVEC) and subcutaneous Matrigel implants. Thymosin beta-4 acted as a chemoattractant for HUVECs in Boyden chamber and scratch-wound assays, increased matrix metalloproteinase production, and increased cell migration into Matrigel implants in vivo. PMID 9194528 · DOI
  4. Pipes GT et al. (2016). Vitamins and hormones. Review of preclinical cardiac ischemia models. Reviewed preclinical studies in which thymosin beta-4 was associated with reduced infarct volume and increased blood vessel growth, attributing effects in part to the SRF-MRTF-G-actin pathway. PMID 27450736 · DOI
  5. Kim J et al. (2016). Vitamins and hormones. Review of hepatic stellate cell studies in vitro and in vivo. Reviewed evidence that exogenous thymosin beta-4 reduced proliferation and migration of activated hepatic stellate cells while endogenously expressed thymosin beta-4 was associated with stellate cell activation. PMID 27450733 · DOI

GHK-Cu

Also known as: Copper tripeptide-1; glycyl-L-histidyl-L-lysine copper(II) complex; GHK; Gly-His-Lys; prezatide copper

Molecular target or pathway: High-affinity Cu(II) chelation (albumin-like copper transport site); modulation of gene expression including collagen, decorin, metalloproteinases and their inhibitors, NF-kB-related and antioxidant genes; integrin expression in keratinocytes; TGF-beta1 secretion in fibroblasts

Origin: Endogenous tripeptide present in human plasma, saliva and urine (originally isolated from human albumin fractions); supplied as a synthetic peptide-copper complex

GHK is a naturally occurring copper-binding tripeptide whose plasma level declines with age; in complex with copper it has been studied in fibroblast, keratinocyte and skin-equivalent cultures, in ex vivo human skin penetration assays, and in rodent, pig and dog wound models. Connectivity Map gene-profiling studies attribute a broad transcriptional footprint to GHK, including collagen, glycosaminoglycan and remodeling genes. Much of the review literature comes from a single author group, and the references below combine those reviews with independent cell-culture studies.

Liv Pure supplies GHK-Cu as a lyophilized research reagent with a lot-specific certificate of analysis.

Selected references

  1. Pickart L et al. (2008). Journal of biomaterials science. Polymer edition. Review (tissue remodeling, cell culture and animal wound models). Reviewed GHK and GHK-Cu copper-binding chemistry and reported effects on chemoattraction of repair cells, collagen and elastin synthesis, metalloproteinase expression, and fibroblast and keratinocyte proliferation across in-vitro and animal models. PMID 18644225 · DOI
  2. Pickart L et al. (2018). International journal of molecular sciences. Review of gene-expression (Connectivity Map) data. Reviewed gene-profiling data indicating that GHK modulates expression of multiple genes and pathways, including those related to collagen synthesis, NF-kB signalling and antioxidant responses. PMID 29986520 · DOI
  3. Choi HR et al. (2012). Journal of peptide science. Cultured normal human keratinocytes and skin-equivalent models. Copper-free GHK increased keratinocyte proliferation and increased α6 and β1 integrin, p63 and PCNA expression in basal cells of skin equivalents, comparable to effects previously reported for copper-GHK. PMID 23019153 · DOI
  4. Gruchlik A et al. (2014). Acta poloniae pharmaceutica. Normal human dermal fibroblasts. GHK, GHK-Cu and free copper ions (1 nM) decreased IGF-2-dependent TGF-β1 secretion in cultured human dermal fibroblasts measured by ELISA. PMID 25745767
  5. Hostynek JJ et al. (2010). Inflammation research. Ex vivo human skin in flow-through diffusion cells. Copper applied as GHK-Cu diacetate permeated dermatomed human skin with a permeability coefficient of 2.43 × 10⁻⁴ cm/h and was retained in skin layers, quantified by ICP-MS. PMID 20703511 · DOI

KPV

Also known as: Lys-Pro-Val; α-MSH(11-13); C-terminal tripeptide of alpha-melanocyte-stimulating hormone

Molecular target or pathway: Melanocortin-related anti-inflammatory signalling with evidence of MC1R-independent activity; intracellular calcium mobilization in keratinocytes; NF-kB pathway modulation; cellular uptake via the oligopeptide transporter PepT1 in intestinal epithelial cells

Origin: Synthetic tripeptide corresponding to the C-terminal residues 11-13 of endogenous alpha-MSH

KPV is the C-terminal tripeptide of alpha-MSH and lacks the core sequence required for classical melanocortin-receptor binding, yet retains much of the parent hormone's anti-inflammatory activity in cell and animal models without pigmentary effects. It has been studied in HaCaT and normal human keratinocytes, MC1R-transfected CHO cells, Caco-2 and RAW 264.7 cells, and in mouse DSS and CD45RB(hi) transfer colitis models, including in MC1R-deficient mice. The precise signalling mechanism is described in reviews as not fully defined.

Liv Pure supplies KPV as a lyophilized research reagent with a lot-specific certificate of analysis.

Selected references

  1. Elliott RJ et al. (2004). The Journal of investigative dermatology. HaCaT and normal human keratinocytes; CHO cells stably expressing MC1R. KPV did not elevate cyclic AMP in keratinocytes but produced rapid intracellular calcium transients in HaCaT cells and in MC1R-transfected CHO cells. PMID 15102092 · DOI
  2. Kannengiesser K et al. (2008). Inflammatory bowel diseases. Mouse DSS colitis and CD45RB(hi) transfer colitis, including MC1R-deficient mice. KPV administration was associated with reduced inflammatory infiltrates and myeloperoxidase activity in colonic tissue, with effects observed in MC1R-nonfunctional mice, indicating partial MC1R independence. PMID 18092346 · DOI
  3. Brzoska T et al. (2010). Advances in experimental medicine and biology. Review (melanocortin peptide signalling). Reviewed evidence that KPV lacks the melanocortin-receptor binding motif yet retains anti-inflammatory activity of alpha-MSH, with an undefined signalling mechanism and no pigmentary action. PMID 21222263 · DOI
  4. Xiao B et al. (2017). Molecular therapy. Colonic epithelial cells, RAW 264.7 macrophages and mouse DSS colitis model. KPV loaded into hyaluronic-acid-functionalized nanoparticles was internalized by colonic epithelial cells and macrophages and was associated with downregulated TNF-α in a mouse colitis model. PMID 28143741 · DOI
  5. Zeng M et al. (2017). ACS applied materials & interfaces. Caco-2 cells overexpressing PepT1 and mouse colitis imaging. A KPV-conjugated fluorescent probe accumulated in Caco-2 cells via PepT1-mediated uptake and localized to inflamed colonic tissue in mouse colitis models. PMID 28349696 · DOI

Frequently asked questions

Which model systems are most commonly used to study tissue-repair peptides?

The published work relies heavily on rat and mouse injury models (Achilles tendon transection, full-thickness dermal wounds, DSS colitis, isoprenaline myocardial injury), ex vivo tendon explant outgrowth assays, and monolayer or Boyden-chamber assays using fibroblasts, keratinocytes (HaCaT, normal human keratinocytes), HUVEC endothelial cells, Caco-2 and RAW 264.7 cells. Readouts typically include cell migration, proliferation, collagen deposition, angiogenesis markers, cytokine levels and gene-expression profiling.

How should lyophilized tissue-repair peptides be stored and handled in the laboratory?

Lyophilized peptides are generally stored desiccated at -20 °C or below and protected from light and moisture; reconstituted solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles. GHK-Cu is a copper complex and can be sensitive to chelators and pH; BPC-157 is reported to be stable in acidic gastric-juice conditions in the primary literature. Researchers should consult the certificate of analysis for each lot and verify identity and purity (e.g. HPLC, mass spectrometry) before use in assays.

What does the literature not cover for these peptides?

For most compounds in this class there are few or no controlled human studies, and much of the BPC-157 and GHK literature originates from a small number of research groups. Receptor-level pharmacology is incompletely characterized (for example, the molecular target of extracellular thymosin beta-4 and the receptor-independent signalling of KPV remain open questions).

All compounds referenced on this page are supplied by Liv Pure for in-vitro laboratory research only and are not for human or animal use. Nothing on this page is medical advice, and no statement here has been evaluated by the Food and Drug Administration. Product identity and purity for each lot are documented on the certificate of analysis; our Testing and Quality page explains what those certificates do and do not measure. Browse the Tissue-Repair Peptides category to see current lots.

Liv Pure

Liv Pure supplies research-grade synthetic peptides and laboratory reagents to qualified researchers and institutions. Every lot ships with a lot-specific certificate of analysis.

Research Use Only • Lot-Specific COAs • Ships From the USA

© 2026 Liv Pure. All rights reserved.

All products provided by Liv Pure are intended solely for in-vitro laboratory research purposes. These materials are expressly forbidden for any form of human or animal use, ingestion, or administration, and all products are sold strictly for research, laboratory, or analytical purposes, not for human consumption. The products offered on this site are not formulated, designed, or intended to diagnose, cure, mitigate, treat, or prevent any disease or medical condition, and these statements have not been evaluated by the Food and Drug Administration. Liv Pure is a chemical supplier; it is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under Section 503B of the Act.